scholarly journals A Case Report of primary cardiac intimal sarcoma presenting with atrial fibrillation and a Left Atrial Mass

Author(s):  
Karen Ho ◽  
Kavya Yatham ◽  
Rommel Seno ◽  
Omar Sultan

Abstract Background Intimal sarcoma is an exceedingly rare type of primary cardiac tumour. It is characterized by poorly differentiated spindle-shaped cells that can mimic smooth muscle and is strongly associated with MDM2 genetic amplification. Owing to its rarity and nondistinctive histological features, diagnosis remains a significant challenge. Case Summary In this case report, we describe a case of primary cardiac intimal sarcoma in a 37-year-old woman who presented with atrial fibrillation and a left atrial mass. Despite having a histological sample from an excised left atrial mass, the diagnosis was not made until she presented with back pain secondary to metastatic disease to the spine. Discussion Primary cardiac intimal sarcoma is an extremely rare diagnosis. The mainstay management of intimal cardiac sarcoma is aggressive surgical resection. Unfortunately, the prognosis of cardiac sarcomas remains very poor, with a mean survival between three months to one year. This case of cardiac intimal sarcoma highlights the difficulty in establishing a diagnosis, particularly given the unusual presentation of atrial fibrillation.

2015 ◽  
Vol 36 (35) ◽  
pp. 2402-2402 ◽  
Author(s):  
Luise Holzhauser ◽  
Johannes Heymer ◽  
Mario Kasner ◽  
Ulf Landmesser ◽  
Carsten Skurk

Author(s):  
James Janopaul-Naylor ◽  
Kirk Kanter ◽  
Thomas Olson ◽  
Bree Eaton

A 13-year-old healthy girl presented with dizziness and palpitations, found to have a left atrial mass. An 8 cm tumor was removed. Pathology confirmed leiomyosarcoma, Grade 3 with positive margins. She was treated with ifosfamide and doxorubicin prior to radiation with concurrent ifosfamide alone. She was treated to 66 Gy in 33 fractions to the operative bed. Prospectively graded toxicities included Gr 2 esophagitis and Gr 1 anorexia, dermatitis and fatigue. She completed a total of 6 cycles of ifosfamide. One year after treatment she had no evidence of disease with normal ECHO and no cardiac, pulmonary or esophageal symptoms.


2006 ◽  
Vol 9 (1) ◽  
pp. E533-E535 ◽  
Author(s):  
Bob Kiaii ◽  
R. Scott McClure ◽  
Alan C. Skanes ◽  
Ian G. Ross ◽  
Alison R. Spouge ◽  
...  

2019 ◽  
Vol 11 (6) ◽  
Author(s):  
Raymond Pranata ◽  
Emir Yonas ◽  
Veresa Chintya ◽  
Alexander Edo Tondas ◽  
Sunu Budhi Raharjo

EP Europace ◽  
2021 ◽  
Vol 23 (Supplement_3) ◽  
Author(s):  
S Kany ◽  
J Brachmann ◽  
T Lewalter ◽  
I Akin ◽  
H Sievert ◽  
...  

Abstract Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Stiftung für Herzinfarkforschung Background  Non-paroxysmal (NPAF) forms of atrial fibrillation (AF) have been reported to be associated with an increased risk for systemic embolism or death compared with paroxysmal AF (PAF). This study investigates the procedural safety and long-term outcomes of left atrial appendage closure (LAAC) in patients with different forms of AF. Methods  Comparison of procedural details and long-term outcomes in patients (pts) with PAF against controls with NPAF in the prospective, multicentre observational registry of patients undergoing LAAC in Germany (LAARGE).  Results  A total of 638 pts (PAF 274 pts, NPAF 364 pts) were enrolled. NPAF consisted of 31.6% patients with persistent AF and 68.4% with longstanding persistent AF or permanent AF. In both groups, a history of PVI was rare (4.0% vs 1.6%, p = 0.066). The PAF group had significantly less history of heart failure (19.0% vs 33.0%, p < 0.001) while the current median LVEF was similar (60% vs 60%, p = 0.26). The total CHA2DS2-VASc score was lower in the PAF group (4.4 ± 1.5 vs 4.6 ± 1.5, p = 0.033), but no difference in the HAS-BLED score (3.8 ± 1.1 vs 3.9 ± 1.1, p = 0.40) was observed. The rate of successful implantation was equally high (97.4% vs 97.8%, p = 0.77) in both groups. In the three-month echo follow-up, device-related thrombi (2.1% vs 7.3%, p = 0.12) and peridevice leak >5 mm (0.0% vs 7.1%, p= 0.53) were numerically higher in the NPAF group. Overall, in-hospital complications occurred in 15.0% of the PAF cohort and 10.7% of the NPAF cohort (p = 0.12). In the one-year follow-up, unadjusted mortality (8.4% vs 14.0%, p = 0.039) and combined outcome of death, stroke and systemic embolism (8.8% vs 15.1%, p = 0.022) were significantly higher in the NPAF cohort. After adjusting for CHA2DS2-VASc and previous bleeding, NPAF was associated with increased death/stroke/systemic embolism (HR 1.67, 95%-CI: 1.02-2.72). Conclusion  Atrial fibrillation type did not impair periprocedural safety or in-hospital MACE of patients undergoing LAAC. However, after one year, NPAF was associated with higher mortality and combined outcome of death, stroke and systemic embolism.


2016 ◽  
Vol 23 (2) ◽  
pp. 147-150
Author(s):  
Elżbieta Malarkiewicz ◽  
Sonia J. Konsek ◽  
Paulina A. Dziamałek ◽  
Grzegorz Wasilewski

Sign in / Sign up

Export Citation Format

Share Document